BioSpace News Archive

Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of a novel autologous immuno-oncology (IO) research platform.

OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), today announced the award of the first U.S. patent for its revolutionary Ultra Shear Technology™ (UST™) platform entitled “System for High Pressure, High Shear Processing of Fluids.

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Biopharmaceuticals Group, at the 2nd Annual Wolfe Research Healthcare Conference on Wednesday, November 18, 2020 at 9:50 a.m. EST.

BioMatrix Specialty Pharmacy announced today that Kionna Oleru, Pharm.D, and manager of the organization’s Columbia, Maryland location, was awarded the prestigious 2020 Next-Generation Pharmacist award in the specialty pharmacy category.

Magnolia Medical Technologies, Inc. today announced the appointment of Gary V. Doern, Ph.D., Professor Emeritus of Pathology, University of Iowa Carver College of Medicine to its Medical & Scientific Advisory Board (MSAB).

Children’s Hospital Los Angeles surgeon, Lorraine Kelley-Quon, MD, forms team of health care providers and community advocates to establish recommendations for safe opioid use

Kepro announced today the appointment of Jay Toth to the company’s executive leadership team as chief growth officer, effective November 2, 2020.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with pediatric cancers, solid tumors and other cancers, today reported its corporate and financial results for the third quarter ended September 30, 2020. Recent Business and Corporate Events: Ewing sarcoma Phase 1/2 clinical trial is completing dose escalation to establish maximum tolerated dose (M